How do I buy Veradermics, Incorporated (MANE) stock?

Buying Veradermics, Incorporated (MANE) stock is now easy and instant through the Gotrade app. Download the Gotrade app from the App Store or Google Play. Create an account and complete KYC. Make a deposit. Search for the code "MANE", then tap "Trade". Tap the "Buy" button. Enter the amount you want to buy. You have two options: Buy MANE by number of shares. Buy fractional shares in dollars, starting from $1. Swipe up to confirm your order, and you're done!

How do I tell if MANE is expensive or cheap?

There's no single perfect answer, but common approaches include: Compare valuation (e.g., P/E, P/S) against historical averages or competitors. Review revenue and earnings growth. Check margins and cash flow. Evaluate business outlook and the company's position within its industry. You can combine fundamental analysis with an investing strategy that matches your risk profile. All of the information above can be viewed directly in the Gotrade app.

Veradermics, Incorporated (MANE) Stock

NYSE · MANE

Trade MANE

116.26

Fundamentals

Market cap

$4.87B

Price / Earnings ratio

-58.0x

Price / Sales ratio

N/A

Price / Book ratio

5.9x

Return on assets

N/A

Ex-Dividend date

N/A

Last payment date

N/A

Dividend amount

$0.00

Dividend yield

0.00%

Debt / Equity ratio

N/A

Technicals

OscillatorsBuy5 Indicators

Moving AveragesStrong Buy10 Indicators

Analyst Ratings

Strong Sell0

Sell0

Neutral0

Buy4

Strong Buy0

Financials

Performance

No data available

Debt & Balance Sheet

No data available

Revenue to Profit

No data available

Earnings

No data available

About Veradermics, Incorporated

The company is a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics to address pervasive treatment challenges in highly prevalent aesthetic and dermatological conditions. Its initial focus is on developing improved treatments for pattern hair loss (PHL), a condition affecting approximately 50 million men and 30 million women in the United States. Current treatment options for PHL are limited and are therefore consistently associated with high rates of treatment failure, patient dissatisfaction, and treatment discontinuation. Patients and healthcare providers routinely identify several shortcomings in existing therapies, including a slow onset of hair growth, inconsistent results, and insufficient hair density to meet patient expectations.

SectorHealthcare

IndustryBiotechnology

Employees37

CEODr. Reid Waldman M.D.

IPO DateFeb 4, 2026

HeadquartersNew Haven, CT

Key Executives

Name	Title	Year Born
Dr. Reid Waldman M.D.	CEO & Director	1995
Mr. Dominic Carrano CPA	CFO & Treasurer	1986
Dr. Timothy Durso M.D.	Chief Technical Officer	1990
Mr. Michael V. Greco J.D.	General Counsel & Secretary	1973
Mr. Karl Pruss	Senior Director of Manufacturing Sciences & Technology	—
Mr. Mark Neumann	Chief Commercial & Strategy Officer	1964
Ms. Erika Sipperly CPA	Controller	—
Dr. Michael Smolinski Ph.D.	Vice President of Development & Scientific Operations	1978
Mr. Aron Shapiro	Vice President of Clinical Development & Regulatory Affairs	1978
Mr. Brian Trautman	Director of CMC Project Management	—

	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec
2026		+21.5	+35.5	+68.4	-0.1	+21.1	-18.3	-3.4	+19.5

FAQ

Buying Veradermics, Incorporated (MANE) stock is now easy and instant through the Gotrade app.

Download the Gotrade app from the App Store or Google Play.
Create an account and complete KYC.
Make a deposit.
Search for the code "MANE", then tap "Trade".
Tap the "Buy" button.
Enter the amount you want to buy. You have two options:
1. Buy MANE by number of shares.
2. Buy fractional shares in dollars, starting from $1.
Swipe up to confirm your order, and you're done!

On Gotrade, you don't have to buy a full lot. With fractional shares, you can start investing in Veradermics, Incorporated from just $1. A small budget shouldn't stop you from building a US stock portfolio.

At the moment, Veradermics, Incorporated (MANE) does not pay dividends because it focuses on reinvesting profits for company growth (a growth stock). However, you can still potentially earn profit from share price increases (capital gains). Track MANE's performance via the price chart in the Gotrade app.

Gotrade is the trading name of Gotrade Securities Inc., which is registered with and supervised by the Labuan Financial Services Authority (LFSA).

You can place orders 24/7. Transactions will be executed when the US market (NYSE/NASDAQ) is open, from 9:30 PM to 4:00 AM WIB. Gotrade also provides access to pre-market and after-hours trading, so you have more flexibility and aren't limited to regular working hours.

Market hours may change due to daylight saving time and holidays. In Gotrade, you can see the market status (open/closed) directly in the app.

There's no single perfect answer, but common approaches include:

Compare valuation (e.g., P/E, P/S) against historical averages or competitors.
Review revenue and earnings growth.
Check margins and cash flow.
Evaluate business outlook and the company's position within its industry.

You can combine fundamental analysis with an investing strategy that matches your risk profile. All of the information above can be viewed directly in the Gotrade app.

Trading Lebih Cepat. Lebih Mudah. Lebih Cerdas.

#ReadyGoTrade

Welcome Reward up to $1,888

Create an account and trade US stocks on Gotrade

Download app

*Terms & conditions apply

Veradermics, Incorporated (MANE) Stock

Fundamentals

Recent news

Veradermics to Present at Upcoming September Investor Conferences

Veradermics to Present at Upcoming September Investor Conferences

Veradermics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress

Veradermics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress

Veradermics Announces Presentations of Data from a Subgroup Analysis of Phase 2/3 Study ‘302' in Males with Pattern Hair Loss at 2026 American Academy of Dermatology Innovation Academy

Veradermics Announces Presentations of Data from a Subgroup Analysis of Phase 2/3 Study ‘302' in Males with Pattern Hair Loss at 2026 American Academy of Dermatology Innovation Academy

Why Is MANE Stock Rising Today?

Why Is MANE Stock Rising Today?

Technicals

Analyst Ratings

Financials

Performance

Debt & Balance Sheet

Revenue to Profit

Earnings

Latest news

Veradermics to Present at Upcoming September Investor Conferences

Veradermics to Present at Upcoming September Investor Conferences

Veradermics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress

Veradermics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress

Veradermics Announces Presentations of Data from a Subgroup Analysis of Phase 2/3 Study ‘302' in Males with Pattern Hair Loss at 2026 American Academy of Dermatology Innovation Academy

Veradermics Announces Presentations of Data from a Subgroup Analysis of Phase 2/3 Study ‘302' in Males with Pattern Hair Loss at 2026 American Academy of Dermatology Innovation Academy

Why Is MANE Stock Rising Today?

Why Is MANE Stock Rising Today?

Veradermics Hair Loss Pill Shows Strong Phase II Signal in Women

Veradermics Hair Loss Pill Shows Strong Phase II Signal in Women

Veradermics' Oral VDPHL01 Delivers Positive Study ‘207' Phase 2 Clinical Trial Results in Female Pattern Hair Loss Ahead of Upcoming Phase 2/3 Study ‘306' Readout

Veradermics' Oral VDPHL01 Delivers Positive Study ‘207' Phase 2 Clinical Trial Results in Female Pattern Hair Loss Ahead of Upcoming Phase 2/3 Study ‘306' Readout

Veradermics to Hold Conference Call to Discuss Study ‘207' Phase 2 Clinical Trial Results of VDPHL01 in Females with Mild-to-Moderate Pattern Hair Loss

Veradermics to Hold Conference Call to Discuss Study ‘207' Phase 2 Clinical Trial Results of VDPHL01 in Females with Mild-to-Moderate Pattern Hair Loss

Can Veradermics (MANE) Climb 27.65% to Reach the Level Wall Street Analysts Expect?

Can Veradermics (MANE) Climb 27.65% to Reach the Level Wall Street Analysts Expect?

Veradermics to Present at Upcoming June Investor Conferences

Veradermics to Present at Upcoming June Investor Conferences

Veradermics Announces Poster Presentation on Topline Results from Phase 2/3 ‘302' Study of VDPHL01 at the 2026 World Congress for Hair Research

Veradermics Announces Poster Presentation on Topline Results from Phase 2/3 ‘302' Study of VDPHL01 at the 2026 World Congress for Hair Research

About Veradermics, Incorporated

Key Executives

Fundamentals

Valuation

Earnings Per Share

Income Statement

Dividend

Solvency

Technicals

What the experts say

Seasonality

Corporate actions

Upcoming

Past

FAQ

Trading Lebih Cepat. Lebih Mudah. Lebih Cerdas.

#ReadyGoTrade